Eisai Announces Results of Overseas Clinical Trials of Donepezil in Treating Vascular Dementia.
Randomized, double-blinded tests were conducted in nine countries with patients with VaD and with no prior diagnosis of Alzheimer's disease. Compared with a placebo group, the subjects receiving donepezil showed significant improvement in cognitive functions but not in global functions.
No statistically significant difference in the occurrence of adverse effects was observed. However, the mortality rate was higher in the donepezil group than the placebo one.
In the US, Japan and the EU, donepezil, under the trade name Aricept, is currently indicated for the treatment of mild to moderate Alzheimer's disease but not for VaD. In the meantime, it is available for the treatment of VaD in India, New Zealand, the Philippines, Romania, South Korea and Thailand.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Mar 17, 2006|
|Previous Article:||Kobayashi Pharmaceutical Introduces New OTC Anemia Treatment.|
|Next Article:||Consumer Finance Companies Set Self-Imposed Limits on TV Advertising.|